Sanofi Asset Resilience Ratio
Sanofi asset resilience ratio. Sanofi (SNYN) has an Asset Resilience Ratio of 0.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Sanofi to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sanofi (2013–2025)
Asset resilience ratio of Sanofi from 2013 to 2025. This chart shows how Sanofi's Asset Resilience Ratio has changed over time. Read SNYN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sanofi's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sanofi assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$810.00 Million | 0.64% |
| Total Liquid Assets | MX$810.00 Million | 0.64% |
Asset Resilience Insights
- Limited Liquidity: Sanofi maintains only 0.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sanofi Industry Peers by Asset Resilience Ratio
Compare Sanofi's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR |
Drug Manufacturers - General | 0.07% |
Sanofi Asset Resilience Ratio by Year (2013–2025)
Sanofi asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Sanofi.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.64% | MX$810.00 Million ≈ $46.62 Million |
MX$126.81 Billion ≈ $7.30 Billion |
+0.27pp |
| 2024-12-31 | 0.37% | MX$486.00 Million ≈ $27.97 Million |
MX$132.80 Billion ≈ $7.64 Billion |
+0.15pp |
| 2023-12-31 | 0.21% | MX$270.00 Million ≈ $15.54 Million |
MX$126.46 Billion ≈ $7.28 Billion |
-0.32pp |
| 2022-12-31 | 0.53% | MX$664.00 Million ≈ $38.21 Million |
MX$124.58 Billion ≈ $7.17 Billion |
-0.34pp |
| 2021-12-31 | 0.88% | MX$1.05 Billion ≈ $60.66 Million |
MX$120.24 Billion ≈ $6.92 Billion |
+0.09pp |
| 2020-12-31 | 0.79% | MX$900.00 Million ≈ $51.80 Million |
MX$114.53 Billion ≈ $6.59 Billion |
+0.41pp |
| 2019-12-31 | 0.38% | MX$426.00 Million ≈ $24.52 Million |
MX$112.74 Billion ≈ $6.49 Billion |
+0.20pp |
| 2018-12-31 | 0.18% | MX$199.00 Million ≈ $11.45 Million |
MX$111.41 Billion ≈ $6.41 Billion |
+0.10pp |
| 2017-12-31 | 0.08% | MX$77.00 Million ≈ $4.43 Million |
MX$99.83 Billion ≈ $5.75 Billion |
+0.05pp |
| 2016-12-31 | 0.03% | MX$31.00 Million ≈ $1.78 Million |
MX$104.67 Billion ≈ $6.02 Billion |
+0.02pp |
| 2015-12-31 | 0.01% | MX$13.00 Million ≈ $748.15K |
MX$102.32 Billion ≈ $5.89 Billion |
+0.00pp |
| 2014-12-31 | 0.01% | MX$9.00 Million ≈ $517.95K |
MX$97.39 Billion ≈ $5.60 Billion |
-0.05pp |
| 2013-12-31 | 0.06% | MX$59.00 Million ≈ $3.40 Million |
MX$96.06 Billion ≈ $5.53 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more